Edgewise Therapeutics’ CMO Trades $32‑plus Shares, Buys at $7‑Deep: Insider’s Dual Play Sparks Investor Curiosity
Edgewise Therapeutics insider activity: CMO Joanne Donovan’s buy‑low and sell‑high trades reveal potential undervaluation and liquidity strategy.
3 minutes to read